These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 38977461)
1. Spinal movement disorders in NMOSD, MOGAD, and idiopathic transverse myelitis: a prospective observational study. Abboud H; Sun R; Modak N; Elkasaby M; Wang A; Levy M J Neurol; 2024 Sep; 271(9):5875-5885. PubMed ID: 38977461 [TBL] [Abstract][Full Text] [Related]
9. The absence of antibodies in longitudinally extensive transverse myelitis may predict a more favourable prognosis. Rocchi C; Forcadela M; Kelly P; Linaker S; Gibbons E; Bhojak M; Jacob A; Hamid S; Huda S Mult Scler; 2024 Mar; 30(3):345-356. PubMed ID: 38258822 [TBL] [Abstract][Full Text] [Related]
10. Plasma Complement 3 and Complement 4 Are Promising Biomarkers for Distinguishing NMOSD From MOGAD and Are Associated With the Blood-Brain-Barrier Disruption in NMOSD. Lin L; Wu Y; Hang H; Lu J; Ding Y Front Immunol; 2022; 13():853891. PubMed ID: 35898513 [TBL] [Abstract][Full Text] [Related]
11. Myelitis in inflammatory disorders associated with myelin oligodendrocyte glycoprotein antibody and aquaporin-4 antibody: A comparative study in Chinese Han patients. ZhangBao J; Huang W; Zhou L; Wang L; Chang X; Lu C; Zhao C; Lu J; Quan C Eur J Neurol; 2021 Apr; 28(4):1308-1315. PubMed ID: 33220172 [TBL] [Abstract][Full Text] [Related]
12. Frequency of Aquaporin-4 Immunoglobulin G in Longitudinally Extensive Transverse Myelitis With Antiphospholipid Antibodies. Guerra H; Pittock SJ; Moder KG; Fryer JP; Gadoth A; Flanagan EP Mayo Clin Proc; 2018 Sep; 93(9):1299-1304. PubMed ID: 29655487 [TBL] [Abstract][Full Text] [Related]
13. The burden of psychiatric morbidity in Multiple Sclerosis, AQP4-antibody NMOSD and MOGAD before and after neurological diagnosis. Tan YY; Saffari SE; Tye JSN; Peng X; Koh MJ; Mahmood ABSB; Tan JMM; Tan K; Yeo T Mult Scler Relat Disord; 2024 Sep; 89():105775. PubMed ID: 39053396 [TBL] [Abstract][Full Text] [Related]
15. Marked central canal T2-hyperintensity in MOGAD myelitis and comparison to NMOSD and MS. Webb LM; Cacciaguerra L; Krecke KN; Chen JJ; Sechi E; Redenbaugh V; Dubey D; Pittock SJ; Flanagan EP J Neurol Sci; 2023 Jul; 450():120687. PubMed ID: 37201267 [TBL] [Abstract][Full Text] [Related]
16. Is Asian type MS an MS phenotype, an NMO spectrum disorder, or a MOG-IgG related disease? Papais Alvarenga RM; Araújo ACRAE; Nascimento ACB; Araujo NEC; Meneguette NS; Neri VC; Papais Alvarenga M; Filho HA; Barros PO; Bento CA; Schmidt SL; Vasconcelos CCF; Alvarenga MP Mult Scler Relat Disord; 2020 Jul; 42():102082. PubMed ID: 32361664 [TBL] [Abstract][Full Text] [Related]
17. Comparative study of AQP4-NMOSD, MOGAD and seronegative NMOSD: a single-center Belgian cohort. Dauby S; Dive D; Lutteri L; Andris C; Hansen I; Maquet P; Lommers E Acta Neurol Belg; 2022 Feb; 122(1):135-144. PubMed ID: 34097296 [TBL] [Abstract][Full Text] [Related]
18. Clinical and immunological differences between MOG associated disease and anti AQP4 antibody-positive neuromyelitis optica spectrum disorders: Blood-brain barrier breakdown and peripheral plasmablasts. Tanaka S; Hashimoto B; Izaki S; Oji S; Fukaura H; Nomura K Mult Scler Relat Disord; 2020 Jun; 41():102005. PubMed ID: 32114369 [TBL] [Abstract][Full Text] [Related]
19. Regional spinal cord volumes and pain profiles in AQP4-IgG + NMOSD and MOGAD. Asseyer S; Zmira O; Busse L; Pflantzer B; Schindler P; Schmitz-Hübsch T; Paul F; Chien C Front Neurol; 2024; 15():1308498. PubMed ID: 38343712 [TBL] [Abstract][Full Text] [Related]
20. The clinical value of complement proteins in differentiating AQP4-IgG-positive from MOG-IgG-positive neuromyelitis optica spectrum disorders. Qin C; Chen B; Tao R; Chen M; Ma X; Shang K; Wu LJ; Wang W; Bu BT; Tian DS Mult Scler Relat Disord; 2019 Oct; 35():1-4. PubMed ID: 31276911 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]